

FILE COPY

Sheet 1 of 9

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1071P1D15	Serial No. 09/724,481
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Clark et al.	
				Filing Date 28 Nov 2000	Group Unknown

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Name	Class	Subclass	Filing Date
PR	* 1 4,411,890	25.10.83	Momany, Frank A.			
	* 2 4,876,242	24.10.89	Applebaum, J. et al.			
	* 3 4,988,675	29.01.91	Froesch et al.			
	* 4 5,068,224	26.11.91	Fryklund et al.			
	* 5 5,077,276	31.12.91	Ballard, F. et al.			
	* 6 5,093,317	03.03.92	Lewis et al.			
	* 7 5,106,832	21.04.92	Froesch et al.			
	* 8 5,126,324	30.06.92	Clark et al.			
	* 9 5,164,370	17.11.92	Ballard, F. et al.			
	* 10 5,187,151	16.02.93	Clark et al.			
	* 11 5,202,119	13.04.93	Clark et al.			
	* 12 5,206,235	27.04.93	Fisher, M. H. et al.			
	* 13 5,210,017	11.05.93	Carlsson, L. et al.			
	* 14 5,223,409	29.06.93	Ladner et al.			
	* 15 5,273,961	28.12.93	Clark			
	* 16 5,374,620	20.12.94	Clark et al.			
	* 17 5,466,670	14.11.95	Dunger, D.B. et al.			
	* 18 5,470,828	28.11.95	Ballard et al.			
	* 19 5,534,617	09.07.96	Cunningham et al.			
	* 20 5,569,648	29.10.96	Lewis, M. et al.			
	* 21 5,593,844	14.01.97	Carlsson, L. et al.			
	* 22 5,597,797	28.01.97	Clark, R.			
	* 23 5,622,932	22.04.97	DiMarchi et al.			
	* 24 5,652,214	29.07.97	Lewis et al.			
	* 25 5,703,045	30.12.97	Lewis et al.			
	* 26 5,714,460	03.02.98	Gluckman et al.			
PR	* 27 5,776,897	07.07.98	Lewis et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Date	Country	Class	Subclass	Translation Yes	Translation No
PR	* 28 128,733	19.12.84	EPO				
	* 29 135,094	27.03.85	EPO				
	* 30 230,869	05.08.87	EPO				
	* 31 288,451	26.10.88	EPO				
	* 32 294,021	07.12.88	EPO				
PR	* 33 369,943	23.05.90	EPO				

Examiner *James Romeo*

Date Considered

10/6/3

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1071P1D15	Serial No. 09/724,481
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Clark et al.	
				Filing Date 28 Nov 2000	Group Unknown

FOREIGN PATENT DOCUMENTS							
Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes No
JKR	* 34	375,438	27.06.90	EPO			
	* 35	379,338	25.07.90	EPO			
	* 36	681,842	15.11.95	EPO			
	* 37	742,228	13.11.96	EPO			
	* 38	965,596	22.12.99	EPO			
	* 39	WO 00/23469	27.04.00	PCT			
	* 40	WO 89/05822	29.06.89	PCT			
	* 41	WO 89/08667	21.09.89	PCT			
	* 42	WO 89/09268	05.10.89	PCT			
	* 43	WO 89/09792	19.10.89	PCT			
	* 44	WO 91/03253	21.03.91	PCT			
	* 45	WO 92/11865	23.07.92	PCT			
	* 46	WO 92/15679	17.09.92	PCT			
	* 47	WO 93/08826	13.05.93	PCT			
	* 48	WO 93/20836	28.10.93	PCT			
	* 49	WO 93/23071	25.11.93	PCT			
	* 50	WO 93/25219	23.12.93	PCT			
	* 51	WO 94/04569	03.03.94	PCT			
	* 52	WO 94/16722	04.08.94	PCT			
	* 53	WO 94/16723	04.08.94	PCT			
	* 54	WO 95/07697	23.03.95	PCT			
	* 55	WO 95/17422	29.06.95	PCT			
	* 56	WO 95/17423	29.06.95	PCT			
	* 57	WO 96/01124	18.01.96	PCT			
	* 58	WO 96/15148	23.05.96	PCT			
	* 59	WO 96/33216	24.10.96	PCT			
	* 60	WO 96/37514	28.11.96	PCT			
	* 61	WO 96/40189	19.12.96	PCT			
	* 62	WO 96/40750	19.12.96	PCT			
	* 63	WO 97/37010	09.10.97	PCT			
	* 64	WO 97/39032	23.10.97	PCT			

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

		Alberts et al. <u>Molecular Biology of the Cell</u> , 3RD edition, New York:Garland Publishing, Inc. pps. 119 (1994)
		Bach and Rechler, "Insulin-like Growth Factor Binding Proteins" <u>Diabetes Reviews</u> 3:38-61 (1995)
		Ballard et al., "Does IGF-I Ever Act Through the Insulin Receptor?" <u>The Insulin-like Growth Factors and Their Regulatory Proteins</u> , Baxter, eds., Amsterdam: Elsevier pps. 131-138 (1994)
JKR	Examiner <i>Daniel Borneo</i>	Date Considered 10/6/3

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449



U.S. Dept. of Commerce

Patent and Trademark Office

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Atty Docket No. P1071P1D15	Serial No. 09/724,481
Applicant Clark et al.	
Filing Date 28 Nov 2000	Group Unknown

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

* 68	Bar et al., "Tissue localization of perfused endothelial cell IGF binding protein is markedly altered by association with IGF-I" <u>Endocrinology</u> 127(6):3243-3245 (1990)
* 69	Bass et al., "Hormone Phage: An Enrichment Method for Variant Proteins with Altered Binding Properties" <u>Proteins: Structure, Function, and Genetics</u> 8(4):309-314 (1990)
* 70	Baxter & Martin, "Binding Proteins for Insulin-Like Growth Factors in Adult Rat Serum. Comparison With Other Human and Rat Binding Proteins" <u>Biochem. & Biophys. Res. Comm.</u> 147(1):408-415 (1987)
* 71	Baxter et al., "Structural determinants for binary and ternary complex formation between insulin-like growth factor-I (IGF-I) and IGF binding protein-3" <u>Journal of Biological Chemistry</u> 267(1):60-65 (Jan 5, 1992)
* 72	Baxter, "Physiological Roles of IGF Binding Proteins" <u>Modern Concepts of Insulin-like Growth Factors</u> , Spencer, eds., Elsevier, New York pps. 371-380 (1991)
* 73	Baxter, "The somatomedins: insulin-like growth factors" <u>Advances in Clinical Chemistry</u> 25:49-115 (1986)
* 74	Baxter, R., "The Insulin-Like Growth Factors and Their Binding Proteins" <u>Comp. Biochem. Physiol.</u> 91B(2):229-235 (1988)
* 75	Bayne et al., "Structural analogs of human insulin-like growth factor I with reduced affinity for serum binding proteins and the type 2 insulin-like growth factor receptor" <u>Journal of Biological Chemistry</u> 263:6233-6239 (1988)
* 76	Bayne et al., "The C region of human insulin-like growth factor (IGF) I is required for high affinity binding to the type 1 IGF receptor" <u>Journal of Biological Chemistry</u> 264(19):11004-11008 (Jul 5, 1989)
* 77	Bayne et al., "The roles of tyrosines 24, 31, and 60 in the high affinity binding of insulin-like growth factor-I to the type I insulin-like growth factor receptor" <u>Journal of Biological Chemistry</u> 265(26):15648-15652 (Sep 15, 1990)
* 78	Binkert et al., "Cloning, sequence analysis and expression of a cDNA encoding a novel insulin-like growth factor binding protein (IGFBP-2)" <u>EMBO Journal</u> 8:2497-2502 (1989)
* 79	Binoux, M., "Donnees recentes sur les somatomedines (Insulin-like growth factors)" <u>Annales d'Endocrinologie</u> 41:157-192 (1980)
* 80	Bondy, C., "Clinical uses of insulin-like growth factor I" <u>Annals of Internal Medicine</u> 120:593-601 (1994)
* 81	Bowers, C. Y., "GH Releasing Peptides - Structure and Kinetics" <u>J. Pediatr. Endocrinology</u> 6(1):21-31 (1993)
* 82	Bowie et al., "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions" <u>Science</u> 247:1306-1310 (1990)
* 83	Brandt et al., "Role of natriuretic peptide clearance receptor in vivo control of C-type natriuretic peptide" <u>American Journal of Physiology</u> 269(1 Pt 2):H326-H331 (Jul 1995)
* 84	Brewer et al., "Cloning, Characterization, and Expression of a Human Insulin-Like Growth Factor Binding Protein" <u>Biochem. & Biophys. Res. Comm.</u> 152(3):1289-1297 (1988)
* 85	Brinkman et al., "Isolation and characterization of a cDNA encoding the low molecular weight insulin-like growth factor binding protein (IBP-1)" <u>The EMBO J.</u> 7:2417-2423 (1988)
* 86	Carlsson et al., "Growth Hormone and Growth in Diabetic Rats: Effects of Insulin and Insulin-Like Growth Factor-I Infusions" <u>J. Endocrinol.</u> 122:661-670 (1989)
* 87	Cascieri et al., "Analysis of the interaction of IGF-I analogs with the IGF-I receptor and IGF binding proteins" <u>Advances in Experimental Medicine & Biology</u> 343:33-40 (1993)


Examiner

Daniel Romeo

Date Considered


10/6/13

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1071P1D15	Serial No. 09/724,481
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)		 Applicant Clark et al.		
		Filing Date 28 Nov 2000	Group Unknown	
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)				
* 88	Cascieri et al., "Mutants of human insulin-like growth factor I with reduced affinity for the type 1 insulin-like growth factor receptor" <i>Biochemistry</i> 27(9):3229-3233 (May 3, 1988)			
* 89	Cascieri et al., "Structural analogs of human insulin-like growth factor (IGF) I with altered affinity for type 2 IGF receptors" <i>Journal of Biological Chemistry</i> 264:2199-2202 (1989)			
* 90	Charlton et al., "Growth hormone-deficient dwarfism in the rat: a new mutation" <i>J. of Endocrinology</i> 119:51-58 (1988)			
* 91	Cheetham et al., "The Effects of Recombinant Human Insulin-like Growth Factor I on Growth Hormone Secretion in Adolescents With Insulin Dependent Diabetes Mellitus" <i>Clin. Endocrinol.</i> 40:515-522 (1994)			
* 92	Cheetham et al., "The Effects of Recombinant Insulin-Like Growth Factor I Administration on Growth Hormone Levels and Insulin Requirements in Adolescents With Type 1 (Insulin-dependent) Diabetes Mellitus" <i>Diabetologia</i> 36:678-681 (1993)			
* 93	Chen et al., "Recombinant human IGF-I infusion results in transient improvement in nitrogen balance: evidence for IGF-I autoregulation" <i>US Endocrine Meeting</i> (Abstract 1596) pps. 449 (1993)			
* 94	Clark et al., "Growth-Responses to Patterned GH Delivery" <i>Endocrine</i> 3:717-723 (1995)			
* 95	Clark et al., "Insulin-Like Growth Factor-1 and Growth Hormone (GH) Have Distinct and Overlapping anabolic Effects in GH-Deficient Rats" <i>Endocrine</i> 3:297-304 (1995)			
* 96	Clemmons and Van Wyk, "Somatomedin: physiological control and effects on cell proliferation" <i>Handbook Exp. Pharmacol.</i> 57:161-208 (1981)			
* 97	Clemmons et al., "Competition for binding to insulin-like growth factor (IGF) binding protein-2, 3, 4, and 5 by the IGFs and IGF analogs" <i>Endocrinology</i> 131(2):890-895 (Aug 1992)			
* 98	Clemmons et al., "Discrete Alterations of the Insulin-like Growth Factor I Molecule Which Alter Its Affinity for Insulin-like Growth Factor-binding Proteins Result in Changes in Bioactivity" <i>Journal of Biological Chemistry</i> 265(21):12210-12216 (1990)			
* 99	Cwirla et al., "Peptides on phage: a vast library of peptides for identifying ligands" <i>Proc. Natl. Acad. Sci. USA</i> 87(16):6378-6382 (1990)			
*100	Devlin et al., "Random peptide libraries: a source of specific protein binding molecules" <i>Science</i> 249:404-406 (1990)			
*101	Duerr et al., "Insulin-Like growth factor-1 enhances ventricular hypertrophy and function during the onset of experimental cardiac failure" <i>J. Clin. Invest.</i> 95:619-627 (1995)			
*102	Elahi et al., "Hemodynamic and metabolic responses to human insulin-like growth factor I (IGF-I) in men" <i>Modern Concepts of Insulin-Like Growth Factors</i> , Spencer, EM, ed., New York:Elsevier Science Publ. Co. pps. 219-224 (1991)			
*103	Fielder et al., "Differential long-term effects of insulin-like growth factor-I (IGF-I) growth hormone (GH), and IGF-I plus GH on body growth and IGF binding proteins in hypophysectomized rats" <i>Endocrinology</i> 137:1913-1920 (1996)			
*104	Franklin et al., "Insulin-Like Growth Factor I Preserves Renal Function Postoperatively" <i>Am. J. Physiol.</i> 272:F257-F259 (1997)			
*105	Froesch et al., "Metabolic and Therapeutic Effects of Insulin-Like Growth Factor I" <i>Horm. Res.</i> 42:66-71 (1994)			
*106	Furnsinn et al., "Insulin-Like Growth Factor-I Inhibits Insulin and Amylin Secretion in Conscious Rats" <i>Endocrinology</i> 135(5):2144-2149 (1994)			
*107	Geysen et al., "A priori delineation of a peptide which mimics a discontinuous antigenic determinant" <i>Molecular Immunology</i> 23(7):709-715 (1986)			
Examiner <i>James R. Davis</i>		Date Considered 10/6/3		
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1071P1D15	Serial No. 09/724,481
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)		O I P E MAR 05 2001 PATENT & TRADEMARK OFFICE		
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)				
JR	*108	Ghazzi et al., "Cardiac and glycemic benefits of troglitazone treatment in NIDDM" <i>Diabetes</i> 46:433-439 (1997)		
	*109	Giebel et al., "Screening of cyclic peptide phage libraries identifies ligands that bind streptavidin with high affinities" <i>Biochemistry</i> 34:15430-15435 (1995)		
	*110	Guler et al., "Effects of Insulin-like Growth Factor I in Man" <i>Acta Paediatr. Scand.</i> 367:52-54 (Suppl. 1990)		
	*111	Guler et al., "Effects of recombinant insulin-like growth factor I on insulin secretion and renal function in normal human subjects" <i>Proc. Natl. Acad. Sci. USA</i> 86:2868-2872 (April 1989)		
	*112	Guler et al., "Insulin-like growth factor I increases glomerular filtration rate and renal plasma flow in man" <i>Acta Endocrinologica</i> 121:101-106 (1989)		
	*113	Guler et al., "Recombinant human insulin-like growth factor I stimulates growth and has distinct effects on organ size in hypophysectomized rats" <i>Proc. Natl. Acad. Sci. USA</i> 85:4889-4893 (1988)		
	*114	Guler et al., "Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults" <i>New England J. of Medicine</i> 317(3):137-140 (1987)		
	*115	Hammerman and Miller, "The growth hormone insulin-like factor axis in kidney revisited" <i>Am. J. Physiol.</i> 265:F1-F14 (1993)		
	*116	Hammerman and Miller, "Therapeutic use of growth factors in renal failure" <i>J. Am. Soc. Nephrol.</i> 5:1-11 (1994)		
	*117	Hampton et al., "Purification and Characterization of an Insulin-like Growth Factor II Variant from Human Plasma" <i>Journal of Biological Chemistry</i> 264(32):19155-19160 (November 15, 1989)		
	*118	Hartman et al., "A low dose euglycemic infusion of recombinant human insulin-like growth factor I rapidly suppresses fasting-enhanced pulsatile growth hormone secretion in humans" <i>J. Clin. Invest.</i> 91:2453-2462 (1993)		
	*119	Hasegawa et al., "The free form of insulin-like growth factor I increases in circulation during normal human pregnancy" <i>J. Clin. Endocrinol. Metabol.</i> 80:3284-3286 (1995)		
	*120	Heding et al., "Biosensor measurement of the binding of insulin-like growth factors I and II and their analogues to the insulin-like growth factor-binding protein-3" <i>Journal of Biological Chemistry</i> 271(24):13948-13952 (Jun 14, 1996)		
	*121	Hirschberg et al., "Effects of insulin-like growth factor I on renal function in normal men" <i>Kidney International</i> 43:387-397 (1993)		
	*122	Hizuka et al., "Measurement of free form of insulin-like growth factor I in human plasma" <i>Growth Regulation</i> 1:51-55 (1991)		
	*123	Humbel, "Insulin-like growth factors I and II" <i>European Journal of Biochemistry</i> 190:445-462 (1990)		
	*124	Jabri et al., "Adverse effects of recombinant human insulin-like growth factor I in obese insulin-resistant type II diabetic patients" <i>Diabetes</i> 43:369-374 (1994)		
	*125	Johnson et al., "Underexpression of β cell high K_m glucose transporters in noninsulin-dependent diabetes" <i>Science</i> 250:546-549 (1990)		
	*126	Jones et al., "Insulin-Like Growth Factors and Their Binding Proteins: Biological Actions" <i>Endocrine Reviews</i> 16(1):3-34 (1995)		
JR	*127	Juul et al., "Serum concentrations of free and total insulin-like growth factor-I, IGF binding proteins -1 and -3 and IGFBP-3 protease activity in boys with normal or precocious puberty" <i>Clin. Endocrinology</i> 44:515-523 (1996)		
Examiner <i>Dianne Romeo</i>			Date Considered 10/6/3	
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1071P1D15	Serial No. 09/724,481
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Clark et al.	
				Filing Date 28 Nov 2000	Group Unknown
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)					
<i>AK</i>	*128	Kay et al., "An M13 phage library displaying random 38-amino-acid peptides as a source of novel sequences with affinity to selected targets" <u>Gene</u> 128:59-65 (1993)			
	*129	Kerr et al., "Effect of Insulin-like Growth Factor 1 on the Responses to and Recognition of Hypoglycemia" <u>Diabetes: American Diabetes Association (ADA)</u> , San Antonio, Texas, June 20-23, 1992 (abstract #225), 52nd Annual Meeting, edition 41(supp 1):60A (Jun 1992)			
	*130	Kerr et al., "Effect of Insulin-like Growth Factor-1 on the Responses to and Recognition of Hypoglycemia in Humans" <u>J. Clin. Invest.</u> 91:141-147 (1993)			
	*131	Kletzien et al., "Enhancement of adipocyte differentiation by an insulin-sensitizing agent" <u>Molecular Pharmacology</u> 41(2):393-398 (Feb 1992)			
	*132	Kupfer et al., "Enhancement of the anabolic effects of growth hormone and insulin-like growth factor I by use of both agents simultaneously" <u>J. Clin. Invest.</u> 91:391-396 (1993)			
	*133	Kuzuya et al., "Trial of insulinlike growth factor I therapy for patients with extreme insulin resistance syndromes" <u>Diabetes</u> 42:696-705 (1993)			
	*134	Lassalle et al., "ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines" <u>Journal of Biological Chemistry</u> 271:20458-20464 (1996)			
	*135	Leahy et al., "Insulin-Like Growth Factor-I at Physiological Concentrations is a Potent Inhibitor of Insulin Secretion" <u>Endocrinology</u> 126(3):1593-1598 (1990)			
	*136	Lee et al., "Insulin-Like Growth Factor (IGF) Binding Protein Complementary Deoxyribonucleic Acid from Human HEP G2 Hepatoma Cells: Predicted Protein Sequence Suggests an IGF Binding Domain Different from Those of the IGF-I and IGF-II Receptors" <u>Mol. Endocrinol.</u> 2(5):404-411 (1988)			
	*137	Lee et al., "Regulation and function of insulin-like growth factor-binding protein-1" <u>Proc. Soc. Exp. Biol. & Med.</u> 204:4-29 (1993)			
	*138	Leung et al., "Growth hormone receptor and serum binding protein: purification, cloning and expression" <u>Nature</u> 330:537-543 (1987)			
	*139	Lewitt and Baxter, "Insulin-like growth factor-binding protein-1: a role in glucose counterregulation?" <u>Mol. Cell. Endocrinology</u> 79(1-3):C147-C152 (1991)			
	*140	Lewitt et al., "Bioavailability of insulin-like growth factors (IGFs) in rats determined by the molecular distribution of human IGF-binding protein-3" <u>Endocrinology</u> 133:1797-1802 (1993)			
	*141	Lewitt et al., "Insulin-like Growth Factor-binding Protein-1 Modulates Blood Glucose Levels" <u>Endocrinology</u> 129(4):2254-2256 (1991)			
	*142	Lieberman et al., "Anabolic effects of recombinant insulin-like growth factor I in AIDS-associated cachexia" <u>US Endocrine Meeting</u> (Abstract 1664) pps. 466 (1993)			
	*143	Lieberman et al., "Anabolic effects of recombinant insulin-like growth factor-I in cachectic patients with the acquired immunodeficiency syndrome" <u>J. Clin. Endocrinol. and Metab.</u> 78(2):404-410 (1994)			
	*144	Lieberman et al., "Effects of recombinant human insulin-like growth factor-I (rhIGF-I) on total and free IGF-I concentrations, IGF-binding proteins, and glycemic response in humans" <u>J. Clin. Endocrinol. and Metab.</u> 75(1):30-36 (1992)			
	*145	Livnah et al., "Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 Å" <u>Science</u> 273(5274):464-471 (Jul 26, 1996)			
	*146	Loddick et al., "Displacement of insulin-like growth factors from their binding proteins as a potential treatment for stroke" <u>Proc. Natl. Acad. Sci. USA</u> 95(4):1894-1898 (Feb 17, 1998)			
<i>AK</i>	*147	Lowman et al., "Molecular mimics of insulin-like growth factor 1 (IGF-1) for inhibiting IGF-1: IGF-binding protein interactions" <u>Biochemistry</u> 37(25):8870-8878 (1998)			
Examiner <i>Howard R. Orms</i>			Date Considered <i>10/6/3</i>		
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>					

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1071P1D15	Serial No. 09/724,481
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)			Applicant Clark et al.	
			Filing Date 28 Nov 2000	Group Unknown
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)				
*148	Maack et al., "Physiological Role of Silent Receptors of Atrial Natriuretic Factor" <u>Science</u> 238:675-678 (Oct 30, 1987)			
*149	Martin & Baxter, "Insulin-like Growth Factor-binding Protein from Human Plasma. Purification and Characterization" <u>Journal of Biological Chemistry</u> 261(19):8754-8760 (1986)			
*150	McLafferty et al., "M13 bacteriophage displaying disulfide-constrained microproteins" <u>Gene</u> 128:29-36 (1993)			
*151	Miller et al., "Effects of IGF-I on renal function in end-stage chronic renal failure" <u>Kidney International</u> 46:201-207 (1994)			
*152	Morrow et al., "Recombinant Human (rh) IGF-1 Reverses Hyperglycemia and Improves Insulin Sensitivity in Severe Insulin Resistance" <u>Diabetes</u> -53rd Annual Meeting, June 12-15, 1993 (abstract No. 269) 42:83A (Suppl. 1 1993)			
*153	O'Neil et al., "Identification of novel peptide antagonists for GPIIB/IIIa from a conformationally constrained phage peptide library" <u>Proteins: Structure, Function, and Genetics</u> 14:509-515 (1992)			
*154	O'Shea and Layish, "Growth hormone and the kidney: a case presentation and review of the literature" <u>J. Am. Soc. Nephrol.</u> 3:157-161 (1992)			
*155	O'Shea et al., "Effects of IGF-I on renal function in patients with chronic renal failure" <u>Am. J. Physiol.</u> 264:F917-F922 (1993)			
*156	Oh et al., "Characterization of the affinities of insulin-like growth factor (IGF)-binding proteins 1-4 for IGF-I, IGF-II, IGF-I/insulin hybrid, and IGF-I analogs" <u>Endocrinology</u> 132:1337-1344 (1993)			
*157	Oh et al., "Synthesis and characterization of insulin-like growth factor-binding protein (IGFBP)-7. Recombinant human mac25 protein specifically binds IGF-I and -II" <u>Journal of Biological Chemistry</u> 271:30322-30325 (1996)			
*158	Oldenburg et al., "Peptide ligands for a sugar-binding protein isolated from a random peptide library" <u>Proc. Natl. Acad. Sci.</u> 89:5393-5397 (1992)			
*159	Peterkofsky et al., "Elevated Activity of Low Molecular Weight Insulin-Like Growth Factor-Binding Proteins in Sera of Vitamin C-Deficient and Fasted Guinea Pigs" <u>Endocrinology</u> 128(4):1769-1779 (1991)			
*160	Quin et al., "Acute Response to Recombinant Insulin-like Growth Factor I in a Patient with Mendenhall's Syndrome" <u>New England J. of Medicine</u> 323:1425-1426 (1990)			
*161	Rinderknecht and H umbel, "Polypeptides with nonsuppressible insulin-like and cell-growth promoting activities in human serum: isolation, chemical characterization, and some biological properties of forms I and II" <u>Proc. Natl. Acad. Sci USA</u> 73(7):2365-2369 (1976)			
*162	Rinderknecht and H umbel, "The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin" <u>Journal of Biological Chemistry</u> 253(8):2769-2776 (1978)			
*163	Ross et al., "The Role of Insulin, Growth Hormone and IGF-I as Anabolic Agents in the Critically Ill" <u>Intensive Care Med.</u> 19(2):S54-S57 (Suppl. 1 1993)			
*164	Rudinger, J., "Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence" <u>Peptide Hormones</u> , J.A. Parsons, Baltimore:University Park Press pps. 1-7 (1976)			
*165	Saad et al., "Low-doses of Insulin-like Growth Factor-I Improve Insulin Sensitivity" <u>Diabetologia</u> (Abstract 152) 37:A40 (Supp. 1 1994)			
*166	Schalch et al., "Short-Term Effects of Recombinant Human Insulin-Like Growth Factor I on Metabolic Control of Patients with Type II Diabetes Mellitus" <u>J. of Clinical Endocrinology & Metabolism</u> 77(6):1563-1568 (1993)			
*167	Schalch et al., "Short-term metabolic effects of recombinant human insulin-like growth factor I (rhIGF-I) in type II diabetes mellitus" <u>Modern Concepts of Insulin-Like Growth Factors</u> , Spencer, ed., New York:Elsevier Science Publ. Co. pps. 705-713 (1991)			
Examiner <i>James Rome</i>	Date Considered <i>10/6/3</i>			
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office	Atty Docket No. P1071P1D15	Serial No. 09/724,481
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)		O I P MAR 05 2001 PC26 PATENT & TRADEMARK OFFICE	Applicant Clark et al.	
OTHER DISCLOSURES (including Author, Title, Date, Pertinent Pages, etc.)				
*168	Schoen et al., "Growth Hormone Secretagogues" <u>Annual Reports in Medicinal Chemistry: Section IV-Immunology, Endocrinology & Metabolic Diseases</u> , William K. Hagmann, Chapter 19, Vol. 28:177-186 (1993)			
*169	Schoenle et al., "Recombinant human insulin-like growth factor I(rhIGF I) reduces hyperglycaemia in patients with extreme insulin resistance" <u>Diabetologia</u> 34:675-679 (1991)			
*170	Scott and Smith, "Searching for peptide ligands with an epitope library" <u>Science</u> 249:386-390 (1990)			
*171	Sherwin et al., "Metabolic Effects of Insulin-like Growth Factor I in Normal Humans" <u>Horm. Res.</u> 41:97-101 (Suppl. 2 1994)			
*172	Skottner et al., "Growth responses in a mutant dwarf rat to human growth hormone and recombinant human insulin-like growth factor I" <u>Endocrinology</u> 124(5):2519-2526 (1989)			
*173	Smith, "Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface" <u>Science</u> 228(4705):1315-1317 (1985)			
*174	Stern et al., "Insulin resistance and pancreatic insulin release in the genetically obese Zucker rat" <u>Proc. Soc. Exp. Biol.</u> 139:66-69 (1972)			
*175	Suikkari et al., "Insulin regulates the serum levels of low molecular weight insulin-like growth factor-binding protein" <u>J. Clin. Endocrinology Metabol.</u> 66:266-272 (1988)			
*176	Swisshein et al., "Enhanced expression of an insulin growth factor-like binding protein (mac25) in senescent human mammary epithelial cells and induced expression with retinoic acid" <u>Proc. Natl. Acad. Sci.</u> 92:4472-4476 (1995)			
*177	Takano et al., "Effects of sc Administration of Recombinant Human Insulin-like Growth Factor I (IGF-I) on Normal Human Subjects" <u>Endocrinol. Japan</u> 37(2):309-317 (1990)			
*178	Tanner et al., "Comparative rapidity of response of height, limb muscle and limb fat to treatment with human growth hormone in patients with and without growth hormone deficiency" <u>Acta Endocrinologica</u> 84:681-696 (1977)			
*179	Underwood et al., "Regulation of somatomedin-c/insulin-like growth factor I by nutrients" <u>Hormone Res.</u> 24:166-176 (1986)			
*180	Usala et al., "Brief report: treatment of insulin-resistant diabetic ketoacidosis with insulin-like growth factor I in an adolescent with insulin-dependent diabetes" <u>New England J. of Medicine</u> 327(12):853-857 (1992)			
*181	Uthne et al., "Effects of human somatomedin preparations on membrane transport and protein synthesis in the isolated rat diaphragm" <u>J. Clin. Endocrinol. Metab.</u> 39(3):548-554 (1974)			
*182	Van Wyk et al., "The somatomedins: a family of insulinlike hormones under growth hormone control" <u>Recent Prog. Horm. Res.</u> 30:259-318 (1974)			
*183	Vlachopapadopoulou et al., "Metabolic and Clinical Response to Recombinant Human Insulin-like Growth Factor I in Myotonic Dystrophy - A Clinical Research Center Study" <u>J. Clin. Endo. Metab.</u> 80(12):3715-3723 (1995)			
*184	Wells and Lowman, "Rapid Evolution of Peptide and Protein Binding Properties in Vitro" <u>Curr. Opin. Struct. Biol.</u> 2:597-604 (1992)			
*185	Wilton et al., "Treatment with recombinant human insulin-like growth factor I of children with growth hormone receptor deficiency (Laron syndrome)" <u>Acta Paediatr Suppl</u> 383:137-142 (1992)			
*186	Wood et al., "Cloning and expression of the growth hormone-dependent insulin-like growth factor-binding protein" <u>Molecular Endocrinology</u> 2:1176-1185 (1988)			
*187	Wood et al., "Crystal structure analysis of deamino-oxytocin: conformational flexibility and receptor binding" <u>Science</u> 232:633-636 (1986)			
Examiner <i>Daniel Bone</i>	Date Considered <i>10/6/3</i>			
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.